79results about How to "Improve in vitro dissolution" patented technology

The present invention relates to a furazolidone tablet preparation method, which is performed according to the following steps: taking furazolidone, a binder and a solubilizer, screening, respectively screening a lubricant and a flow aid with a 80-120 mesh sieve, adding water or an alcohol to the partial binder having the content of more than or equal to 28% of the total amount of the binder and the partial solubilizer having the content of more than or equal to 14% of the total amount of the solubilizer to prepare a binder solution with a mass concentration of 1-30%, uniformly mixing the remaining binder and the remaining solubilizer, uniformly mixing with the furazolidone according to an equivalent gradual increase method, adding the binder solution to prepare a soft material, carrying out 12-30 mesh pelletization, drying at a temperature of less than 70 DEG C, carrying out 12-30 mesh granulating, adding a lubricant and a flow aid, uniformly mixing, and tabletting to obtain the finished product. According to the present invention, the reasonable process operation sequence is adopted, the part of the solubilizer is adopted to increase furazolidone hydrophilicity, and the part of the solubilizer is adopted to promote furazolidone self-emulsifying and increase solubility in water so as to improve a dissolution rate and increase bioavailability.

The invention relates to a terbinafine hydrochloride solid dispersoid, which is composed of terbinafine hydrochloride and carrier materials, wherein the proportion by weight between the terbinafine hydrochloride and the carrier materials is 1 / 2-1 / 15. The invention further relates to a tablet prepared by the terbinafine hydrochloride solid dispersoid. Compared with the prior art, the terbinafine hydrochloride tablet has the advantages of (1) improving dissolution in vitro of terbinafine hydrochloride preparation; (2) solving the problem that the terbinafine hydrochloride is poor in oral administration absorption and low in biological availability; (3) covering harmful odor and irritation of the terbinafine hydrochloride; (4) keeping pesticide effects of large dose while reducing using quantity of active ingredients in the preparation per unit, and reducing drug side-effects; and (5) being simple in preparation process and suitable for industrial production.

The invention provides a probucol orally administered nanometer solid preparation, which comprises, by weight, 1 part of probucol, 0.01-0.1 part of additive and 0.05-0.4 part of auxiliary materials. The grain size of the probucol ranges from 10nm to 200nm. The invention further provides a preparation method for the probucol orally administered nanometer solid preparation. The preparation method includes that the probucol and water liquor with 5% of additive are prepared into nanometer suspension with the grain size ranging from 100nm to 600nm by a wet grinding method; the nanometer suspension is homogenized into nanometer grains with the grain sizes ranging from 10nm to 200nm by a high-pressure homogenizing machine; and the nanometer suspension which is homogenized is solidified and is added with the auxiliary materials to be prepared into the orally administered nanometer solid preparation. Compared with a common probucol tablet, the preparation has the advantages that dissolution in vitro of the preparation is increased by 20-30 times, and bioavailability after oral administration is improved by 10-20 times. In addition, the drug loading rate of the preparation is high, and the preparation can meet the requirements of tablet weight clinically needed by high-dose probucol administration. Besides, the preparation is stable, and the dissolution of the preparation can be kept unchanged within two years.

A dispersed solid or orally taken composition of gliben clamide clamide is prepared from glibenclamide and dispersing medium proportionally through mixing, grinding and fusing or spray drying.